Institution
Northwood University
Education•Midland, Michigan, United States•
About: Northwood University is a education organization based out in Midland, Michigan, United States. It is known for research contribution in the topics: Radiation therapy & Cancer. The organization has 951 authors who have published 1347 publications receiving 42341 citations.
Topics: Radiation therapy, Cancer, Brachytherapy, Breast cancer, Population
Papers published on a yearly basis
Papers
More filters
••
Mater Health Services1, University of Sydney2, National and Kapodistrian University of Athens3, The Royal Marsden NHS Foundation Trust4, University of Tübingen5, University of Kiel6, Aix-Marseille University7, Paris Diderot University8, Sir Charles Gairdner Hospital9, Netherlands Cancer Institute10, Karolinska University Hospital11, Heidelberg University12, German Cancer Research Center13, Northwood University14, Institut Gustave Roussy15, University of Paris-Sud16, University of California, Los Angeles17, Novartis18, Merck & Co.19, Harvard University20
TL;DR: The improvement in overall survival establishes the combination of dabrafenib and trametinib as the standard targeted treatment for BRAF Val600 mutation-positive melanoma.
1,099 citations
••
New York University1, Lunenfeld-Tanenbaum Research Institute2, Northwood University3, Ghent University Hospital4, Johns Hopkins University School of Medicine5, Brigham and Women's Hospital6, Paris Descartes University7, Cornell University8, University of Fribourg9, University of Cincinnati Academic Health Center10, Yale University11
TL;DR: The PI-RADS Steering Committee, using a consensus-based process, has recommended several modifications to PI- RADS v2, maintaining the framework of assigning scores to individual sequences and using these scores to derive an overall assessment category.
1,053 citations
••
Memorial Sloan Kettering Cancer Center1, Cleveland Clinic2, Beth Israel Deaconess Medical Center3, Johns Hopkins University4, Institut Gustave Roussy5, Katholieke Universiteit Leuven6, Roswell Park Cancer Institute7, Rabin Medical Center8, Fred Hutchinson Cancer Research Center9, Sheba Medical Center10, Fox Chase Cancer Center11, University Medical Center Groningen12, University of Michigan13, Palacký University, Olomouc14, Queen Mary University of London15, Northwood University16, Brigham and Women's Hospital17, Aarhus University Hospital18, Macquarie University19, University of Calgary20, Durham University21, Niigata University22, Bristol-Myers Squibb23, University of Texas MD Anderson Cancer Center24
TL;DR: Results showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival and characterisation of response, and safety after extended follow-up in intermediate-risk or poor-risk patients.
Abstract: Summary Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting. Methods In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status into favourable-risk, intermediate-risk, and poor-risk subgroups and randomly assigned (1:1) to open-label nivolumab (3 mg/kg intravenously) plus ipilimumab (1 mg/kg intravenously) every 3 weeks for four doses, followed by nivolumab (3 mg/kg intravenously) every 2 weeks; or sunitinib (50 mg orally) once daily for 4 weeks (6-week cycle). Randomisation was done through an interactive voice response system, with a block size of four and stratified by risk status and geographical region. The co-primary endpoints for the trial were overall survival, progression-free survival per independent radiology review committee (IRRC), and objective responses per IRRC in intermediate-risk or poor-risk patients. Secondary endpoints were overall survival, progression-free survival per IRRC, and objective responses per IRRC in the intention-to-treat population, and adverse events in all treated patients. In this Article, we report overall survival, investigator-assessed progression-free survival, investigator-assessed objective response, characterisation of response, and safety after extended follow-up. Efficacy outcomes were assessed in all randomly assigned patients; safety was assessed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT02231749, and is ongoing but now closed to recruitment. Findings Between Oct 16, 2014, and Feb 23, 2016, of 1390 patients screened, 1096 (79%) eligible patients were randomly assigned to nivolumab plus ipilimumab or sunitinib (550 vs 546 in the intention-to-treat population; 425 vs 422 intermediate-risk or poor-risk patients, and 125 vs 124 favourable-risk patients). With extended follow-up (median follow-up 32·4 months [IQR 13·4–36·3]), in intermediate-risk or poor-risk patients, results for the three co-primary efficacy endpoints showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival (median not reached [95% CI 35·6–not estimable] vs 26·6 months [22·1–33·4]; hazard ratio [HR] 0·66 [95% CI 0·54–0·80], p Interpretation The results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib was maintained in intermediate-risk or poor-risk and intention-to-treat patients with extended follow-up, and show the long-term benefits of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma across all risk categories. Funding Bristol-Myers Squibb and ONO Pharmaceutical.
527 citations
••
Institute of Cancer Research1, Keele University2, Royal Cornwall Hospital3, Beatson West of Scotland Cancer Centre4, University of Sussex5, Worcestershire Acute Hospitals NHS Trust6, University of Cambridge7, Torbay Hospital8, Norfolk and Norwich University Hospital9, The Royal Marsden NHS Foundation Trust10, University of Manchester11, Northwood University12, King's College London13, Clatterbridge Cancer Centre NHS Foundation Trust14
TL;DR: 26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breast cancer.
519 citations
••
University of Sydney1, Harvard University2, National and Kapodistrian University of Athens3, University of Tübingen4, Paris Diderot University5, Sir Charles Gairdner Hospital6, Dniepropetrovsk State Medical Academy7, Netherlands Cancer Institute8, Karolinska University Hospital9, German Cancer Research Center10, Northwood University11, University of Paris-Sud12, University of California, Los Angeles13, University of Texas MD Anderson Cancer Center14, Novartis15, Aix-Marseille University16
TL;DR: It is demonstrated that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.
483 citations
Authors
Showing all 954 results
Name | H-index | Papers | Citations |
---|---|---|---|
Søren M. Bentzen | 94 | 537 | 32702 |
George S. Wilson | 88 | 716 | 33034 |
Anwar R. Padhani | 82 | 342 | 24783 |
Peter Hoskin | 82 | 585 | 29453 |
Ian D. Wilson | 80 | 594 | 33379 |
Stanford R. Ovshinsky | 75 | 393 | 23001 |
Tim Meyer | 74 | 548 | 24784 |
Ian J. Stratford | 68 | 368 | 17663 |
Gordon J. S. Rustin | 67 | 199 | 20241 |
Fu-Chan Wei | 66 | 331 | 14246 |
Mark Bower | 65 | 420 | 15164 |
Vicky Goh | 55 | 243 | 11232 |
David J. Chaplin | 54 | 184 | 9360 |
Rob Glynne-Jones | 53 | 266 | 12146 |
Peter Wardman | 50 | 155 | 8219 |